TNFSF10 and glioblastoma: These findings demonstrate that all predictions regarding ABT-737-based sensitization could be validated (8/8), with our approach able to identify the subset of GBM cell lines that could be successfully sensitized to TRAIL by ABT-737 co-treatment.